01

Dec2017

Proposed Amendments to Patented Medicines Regulations Announced

Proposed regulatory text of amendments to the Patented Medicines Regulations is published by the Governor-in-Council in Canada Gazette Part I (CG1) on December 2, 2017.  Interested persons may submit comments on the proposed regulations within 75 days of publication in CG1 (by ... Read More

01

Nov2017

PMPRB 2016 Annual Report Released

The Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, released its Annual Report for the year ended December 31, 2016. The Annual Report is an extensive document that reviews all of the PMPRB’s major activities, analyses of the prices of patented ... Read More

29

Sep2017

PMPRB Hearing Panel Decision Released: Soliris

The Hearing Panel of the Patented Medicine Prices Review Board has made public its decision in the matter of Alexion Pharmaceuticals Inc. and the medicine Soliris. The Panel orders Alexion to: pay to Her Majesty in right of Canada an amount calculated by the parties in accordance with Schedule ... Read More

23

Aug2017

NOW LIVE: PDCI’s Information Sharing Webpage: Responses to Health Canada’s Patented Medicines Regulations Consultation

PDCI has now published its information sharing webpage which aggregates submissions made by individuals and organizations in response to Health Canada’s Consultation on Proposed Amendments to the Patented Medicines Regulations. Click Here to Visit PDCI’s Information Sharing Webpage. The submissions have been provided by individuals & organizations on a completely voluntary ... Read More

22

Aug2017

Sharing Responses on Proposed Amendments to the Patented Medicines Regulations

***Participation Requested*** Sharing Responses to Health Canada’s Consultation on Proposed Amendments to the Patented Medicines Regulations In May 2017, Federal Minister of Health Jane Philpott, launched a consultation on proposed amendments to the Patented Medicines Regulations that would have significant effects on how patented ... Read More

30

May2017

The PMPRB Releases its May 2017 NEWSletter

Consultation on Potential Changes to the Patented Medicines Regulations On May 16, 2017, the Honourable Jane Philpott, Minister of Health, outlined a comprehensive plan for improving the pharmaceutical system in Canada. Included in the plan was the launch of a consultation process on potential changes to the Patented Medicines Regulations (Regulations) ... Read More

25

May2017

PDCI Market Access Webinar: Information Session for Industry on Proposed Amendments to Patented Medicines Regulations

On Tuesday, May 16, 2017, Federal Health Minister Hon. Jane Philpott opened consultations on a suite of amendments to the Patented Medicines Regulations that will have significant effects on how patented drug prices are regulated in Canada. The implementation of these proposed amendments could represent the most important changes in ... Read More

16

May2017

Patented Medicines Regulations Consultation Open

Health Minister Hon. Jane Philpott Announces Consultations on proposed changes to the Patented Medicines Regulations Speaking today at the Economic Club of Canada in Ottawa, Federal Health Minister Jane Philpott announced the opening of a consultation period concerning proposed changes to the Patented Medicines Regulations that would have significant effects ... Read More

19

Apr2017

New NPDUIS Report Released – PMPRB Meds Entry Watch

The new PMPRB Meds Entry Watch annual publication explores the market entry dynamics of new drugs launched in Canada and other international markets. This first edition of the report provides both a retrospective analysis of the new drugs launched over a six-year period from 2009 to 2014, and an early ... Read More

17

Feb2017

PMPRB Form 3 Reminder

This is a reminder to all patentees of their filing requirements to the PMPRB respecting revenues and research and development expenditures. All patentees must submit their Form 3 information for 2016 by March 1, 2017. These filing requirements are contained in section 5 of the Patented Medicines Regulations. As part of their ... Read More